Weekly paclitaxel with and without concurrent radiation therapy

Toxicity, pharmacokinetics, and response

M. J. Glantz, H. Choy, W. Akerley, C. M. Kearns, M. J. Egorin, C. H. Rhodes, B. F. Cole

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has shown in vitro and clinical activity against non-small cell lung cancer and astrocytic brain tumors, tumors traditionally believed to be relatively resistant to chemotherapy and radiotherapy. Because of its ability to block dividing cells in the G2/M portion of the cell cycle (the most radiosensitive phase of the cell cycle), paclitaxel is also a potentially potent radiosensitizer. To investigate these and other properties of paclitaxel, we have explored a weekly, outpatient administration schedule, with and without concurrent radiation therapy, in patients with non-small cell lung and astrocytic brain tumors. Our experience has shown that weekly, outpatient administration is feasible; that remarkably high dose intensities can be achieved with acceptable toxicity; and that the specific dose- limiting toxicity appears to depend on administration schedule, type of concurrent radiotherapy, and certain patient characteristics. Preliminary response data are very encouraging. At the same time, pharmacokinetic studies have suggested possible reasons for our ability to use such exorbitant dose intensities safely and have also shown that sustained plasma paclitaxel levels above the putative radiosensitizing threshold can be achieved continuously during a 6-week course of radiotherapy. Specific results, dosing recommendations, and plans for future studies are discussed.

Original languageEnglish (US)
JournalSeminars in Radiation Oncology
Volume7
Issue number2 SUPPL. 1
StatePublished - 1997

Fingerprint

Paclitaxel
toxicity
radiation therapy
Radiotherapy
Pharmacokinetics
tumors
Brain Neoplasms
schedules
dosage
lungs
brain
Appointments and Schedules
Cell Cycle
Outpatients
cycles
chemotherapy
recommendations
Non-Small Cell Lung Carcinoma
cancer
thresholds

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology
  • Radiation

Cite this

Glantz, M. J., Choy, H., Akerley, W., Kearns, C. M., Egorin, M. J., Rhodes, C. H., & Cole, B. F. (1997). Weekly paclitaxel with and without concurrent radiation therapy: Toxicity, pharmacokinetics, and response. Seminars in Radiation Oncology, 7(2 SUPPL. 1).

Weekly paclitaxel with and without concurrent radiation therapy : Toxicity, pharmacokinetics, and response. / Glantz, M. J.; Choy, H.; Akerley, W.; Kearns, C. M.; Egorin, M. J.; Rhodes, C. H.; Cole, B. F.

In: Seminars in Radiation Oncology, Vol. 7, No. 2 SUPPL. 1, 1997.

Research output: Contribution to journalArticle

Glantz, MJ, Choy, H, Akerley, W, Kearns, CM, Egorin, MJ, Rhodes, CH & Cole, BF 1997, 'Weekly paclitaxel with and without concurrent radiation therapy: Toxicity, pharmacokinetics, and response', Seminars in Radiation Oncology, vol. 7, no. 2 SUPPL. 1.
Glantz, M. J. ; Choy, H. ; Akerley, W. ; Kearns, C. M. ; Egorin, M. J. ; Rhodes, C. H. ; Cole, B. F. / Weekly paclitaxel with and without concurrent radiation therapy : Toxicity, pharmacokinetics, and response. In: Seminars in Radiation Oncology. 1997 ; Vol. 7, No. 2 SUPPL. 1.
@article{8a6e0306b7884f4b9da332324d8c2515,
title = "Weekly paclitaxel with and without concurrent radiation therapy: Toxicity, pharmacokinetics, and response",
abstract = "Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has shown in vitro and clinical activity against non-small cell lung cancer and astrocytic brain tumors, tumors traditionally believed to be relatively resistant to chemotherapy and radiotherapy. Because of its ability to block dividing cells in the G2/M portion of the cell cycle (the most radiosensitive phase of the cell cycle), paclitaxel is also a potentially potent radiosensitizer. To investigate these and other properties of paclitaxel, we have explored a weekly, outpatient administration schedule, with and without concurrent radiation therapy, in patients with non-small cell lung and astrocytic brain tumors. Our experience has shown that weekly, outpatient administration is feasible; that remarkably high dose intensities can be achieved with acceptable toxicity; and that the specific dose- limiting toxicity appears to depend on administration schedule, type of concurrent radiotherapy, and certain patient characteristics. Preliminary response data are very encouraging. At the same time, pharmacokinetic studies have suggested possible reasons for our ability to use such exorbitant dose intensities safely and have also shown that sustained plasma paclitaxel levels above the putative radiosensitizing threshold can be achieved continuously during a 6-week course of radiotherapy. Specific results, dosing recommendations, and plans for future studies are discussed.",
author = "Glantz, {M. J.} and H. Choy and W. Akerley and Kearns, {C. M.} and Egorin, {M. J.} and Rhodes, {C. H.} and Cole, {B. F.}",
year = "1997",
language = "English (US)",
volume = "7",
journal = "Seminars in Radiation Oncology",
issn = "1053-4296",
publisher = "W.B. Saunders Ltd",
number = "2 SUPPL. 1",

}

TY - JOUR

T1 - Weekly paclitaxel with and without concurrent radiation therapy

T2 - Toxicity, pharmacokinetics, and response

AU - Glantz, M. J.

AU - Choy, H.

AU - Akerley, W.

AU - Kearns, C. M.

AU - Egorin, M. J.

AU - Rhodes, C. H.

AU - Cole, B. F.

PY - 1997

Y1 - 1997

N2 - Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has shown in vitro and clinical activity against non-small cell lung cancer and astrocytic brain tumors, tumors traditionally believed to be relatively resistant to chemotherapy and radiotherapy. Because of its ability to block dividing cells in the G2/M portion of the cell cycle (the most radiosensitive phase of the cell cycle), paclitaxel is also a potentially potent radiosensitizer. To investigate these and other properties of paclitaxel, we have explored a weekly, outpatient administration schedule, with and without concurrent radiation therapy, in patients with non-small cell lung and astrocytic brain tumors. Our experience has shown that weekly, outpatient administration is feasible; that remarkably high dose intensities can be achieved with acceptable toxicity; and that the specific dose- limiting toxicity appears to depend on administration schedule, type of concurrent radiotherapy, and certain patient characteristics. Preliminary response data are very encouraging. At the same time, pharmacokinetic studies have suggested possible reasons for our ability to use such exorbitant dose intensities safely and have also shown that sustained plasma paclitaxel levels above the putative radiosensitizing threshold can be achieved continuously during a 6-week course of radiotherapy. Specific results, dosing recommendations, and plans for future studies are discussed.

AB - Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has shown in vitro and clinical activity against non-small cell lung cancer and astrocytic brain tumors, tumors traditionally believed to be relatively resistant to chemotherapy and radiotherapy. Because of its ability to block dividing cells in the G2/M portion of the cell cycle (the most radiosensitive phase of the cell cycle), paclitaxel is also a potentially potent radiosensitizer. To investigate these and other properties of paclitaxel, we have explored a weekly, outpatient administration schedule, with and without concurrent radiation therapy, in patients with non-small cell lung and astrocytic brain tumors. Our experience has shown that weekly, outpatient administration is feasible; that remarkably high dose intensities can be achieved with acceptable toxicity; and that the specific dose- limiting toxicity appears to depend on administration schedule, type of concurrent radiotherapy, and certain patient characteristics. Preliminary response data are very encouraging. At the same time, pharmacokinetic studies have suggested possible reasons for our ability to use such exorbitant dose intensities safely and have also shown that sustained plasma paclitaxel levels above the putative radiosensitizing threshold can be achieved continuously during a 6-week course of radiotherapy. Specific results, dosing recommendations, and plans for future studies are discussed.

UR - http://www.scopus.com/inward/record.url?scp=0030965252&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030965252&partnerID=8YFLogxK

M3 - Article

VL - 7

JO - Seminars in Radiation Oncology

JF - Seminars in Radiation Oncology

SN - 1053-4296

IS - 2 SUPPL. 1

ER -